Baricitinib

• Description:

  Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

• Product Name Alternative:

  LY3009104; INCB028050

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Baricitinib.html

• Purity:

  99.97

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming)

• Smiles:

  N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1

• Molecular Formula:

  C16H17N7O2S

• Molecular Weight:

  371.42

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184 (9) :5298-307.|[2]Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2 (4) :351-5.|[3]Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration resistance. Int J Obes (Lond) . 2015 Nov;39 (11) :1607-18.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  JAK1; JAK2; JAK3; Tyk2

• Citation 01:

  ACS Nano. 2024 Mar 19;18 (11) :8337-8349.|Acta Pharmacol Sin. 2021 May;42 (5) :814-823.|Adv Sci (Weinh) . 2020 Sep 24;7 (21) :2002518.|Adv Sci (Weinh) . 2024 Dec 5:e2410360.|Aging Cell. 2025 Oct 20:e70273.|Ann Rheum Dis. 2025 Sep 25:S0003-4967 (25) 04383-3.|bioRxiv. 2018 Feb.|bioRxiv. 2020 Jun.|bioRxiv. 2020 Mar.|bioRxiv. 2024 Jul 12:2024.07.11.603146.|bioRxiv. 2024 Jul 7:2024.07.04.601620.|bioRxiv. 2025 April 12.|bioRxiv. 2025 February 21.|bioRxiv. 2025 Jul 29.|bioRxiv. 2025 Jul 31.|bioRxiv. 2025 Sep 10:2025.09.05.673576.|bioRxiv. 2025 Sep 24.|Br J Pharmacol. 2024 Dec;181 (23) :4804-4821.|Cancer Res. 2021 Dec 15;81 (24) :6131-6141.|Cell Death Dis. 2025 Jul 11;16 (1) :512.|Cell. 2021 Apr 15;184 (8) :2167-2182.e22.|Chemrxiv. 2023 Aug 3.|Chemrxiv. Aug 11, 2021.|Diabetologia. 2024 Jan;67 (1) :124-136.|Drug Resist Updat. 2025 Jul:81:101224.|Eur J Pharm Sci. 2024 Jul 4:106845.|Heliyon. 2018 Nov 26;4 (11) :e00979.|Immunol Res. 2025 Jun 26;73 (1) :99.|Inflammation. 2021 Feb;44 (1) :206-216.|Institute of Natural Medicine, University of Toyama, Japan. 2018, Nov.|Int Immunopharmacol. 2022 Sep:110:109044.|Int Immunopharmacol. 2024 Aug 9:140:112894.|Int J Mol Sci. 2025 May 19;26 (10) :4849.|Int J Obes (Lond) . 2015 Nov;39 (11) :1607-18. |J Allergy Clin Immunol. 2024 Apr;153 (4) :1125-1139.|J Autoimmun. 2022 Feb;127:102793.|J Clin Invest. 2021 Dec 15;131 (24) :e145501.|J Dermatol Sci. 2024 Oct 22.|J Exp Med. 2024 Mar 4;221 (3) :e20230683.|J Immunol. 2013 Oct 1;191 (7) :3568-77. |J Immunother Cancer. 2025 May 11;13 (5) :e010831.|Karolinska Institutet. 2024 May 31.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Mol Ther Nucleic Acids. 2025 Mar 5;36 (2) :102502. |Nat Commun. 2023 Apr 24;14 (1) :2342.|Pharmacol Rep. 2024 Oct;76 (5) :1079-1088.|Phytomedicine. 2025 Nov 25:150:157605.|Platelets. 2022 Apr 3;33 (3) :404-415.|PLoS One. 2017 Jul 14;12 (7) :e0181126.|Proc Natl Acad Sci U S A. 2025 Aug 19;122 (33) :e2514837122.|Res Sq. 2024 Jul 16.|Research Square Preprint. 2024 Mar 21.|Rheumatology (Oxford) . 2023 Aug 1;62 (8) :2908-2917.|RSC Adv. 2018, 8, 21534-21540.|Sci Adv. 2024 Mar 22;10 (12) :eadl0368.|Sci Immunol. 2024 Jul 12;9 (97) :eadn0178.|Sci Rep. 2022 May 12;12 (1) :7843.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Science. 2017 Dec 1;358 (6367) :eaan4368.|Signal Transduct Target Ther. 2021 Apr 24;6 (1) :165.|SSRN. 2025 Jul 30.|Toxicol Sci. 2020 Aug 1;176 (2) :410-422.|University of Greifswald. 2025.|bioRxiv. 2020 Nov 6:2020.10.04.325415.|Commun Biol. 2021 Jun 2;4 (1) :654.|J Clin Invest. 2024 Oct 1;134 (19) :e176828.|JHEP Rep. 2025 Nov 6.|Research Square Preprint. 2020 Dec 11:rs.3.rs-119695.

• CAS Number:

  [1187594-09-7]